Volume 8 Number 11/12 November/December 2007

11th European AIDS conference (EACS), October 24-27 2007, Madrid

New European guidelines launched (2007)

Saquinavir/r non-inferior to Kaletra at week 48 (Gemini study)

Darunavir once-daily is non-inferior to lopinavir/r in treatment-naive patients at 48 weeks (Artemis study)

Tesamorelin (TH9507) reduces abdominal fat in patients with HIV-related lipodystrophy: 52 week results

Drug interaction studies presented at EACS

HIV and TB co-infection and treatment charges in the UK

US adult treatment guidelines updated (December 2007)

Half-dose Kaletra tablet approved for paediatric use in the US

Case report of efavirenz-associated nephrolithiasis

Yellow card reporting scheme for doctors and patients in the UK

US updates guidelines on use of ARVs during pregnancy (Dec 2007)

Perinatal transmission of HIV in England 2002-2005

Risk factors for in utero or intrapartum mother-to-child transmission in Thailand

New drug interaction summary tables: maraviroc, integrase inhibitors, etravirine, hormonal contraceptives

Acid reducing agents and protese inhibitors

Atazanavir, with or without ritonavir, may increase buprenorphine and buprenorphine metabolites, requiring dose adjustment

T-20 increases tipranavir levels but not hepatotoxicity

The effect of lopinavir/r on the renal clearance of tenofovir

Merck HIV vaccine trial is unblinded

IAS statement on US policy for HIV-positive visitors

PLoS Medicine articles

HIV/TB co-infection: meeting the challenge

Volume 8 Number 11/12 November/December 2007 PDF

Volume 8 Number 10 October 2007

BHIVA Autumn conference, 11-12 October 2007, London

Audit of treating naive patients showed basic UK guidelines not followed in over 25% patients; 60% patients start with a CD4 count <200 cells/mm3

Donor governments pledge record amounts to the Global Fund

Atripla approved in Europe as switch option for suppressed patients

Maraviroc approved in Europe for treatment-experienced CCR5-tropic patients

Paediatric formulation of fosamprenavir approved in Europe

Raltegravir approved in the US

EMEA recommends reinstating license for Roche’s nelfinavir

Roche withdraw application for Biojector needle-free option for T-20

Antiretroviral drug exposure in the female genital tract

Hormonal contraceptive use, herpes simplex virus infection, and risk of HIV-1 acquisition among Kenyan women

Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women’s Interagency HIV Study

Pregnancy shows a positive impact on HIV disease progression

African infants CCL3 gene copies influence perinatal HIV transmission in the absence of maternal nevirapine prophylaxis

Low rates of mother to child transmission in the DREAM and MTCT-Plus programmes

Risk factors for early mortality for children receiving divided adult fixed dose combination tablets in Malawi

Risk of antibody negative HCV infection in four US HIV cohorts: risk linked to IDU, elevated ALT and low CD4 count

Survival of HIV-positive IDUs in the era of HAART

Current or former injecting drug use is not related to earlier switch or discontinuation of HAART compared to non-IDU patients since 1999

Merck HIV vaccine trial halted by DSMB for lack of efficacy

Free full text articles

Conference abstracts and presentations

Volume 8 Number 10 October 2007 PDF

Volume 8 Number 8/9 August/September 2007

Update on nelfinavir recall: plan for safety registries

Pfizer issue Dear Doctor letter over EMS content in US formulation of nelfinavir

4th IAS Conference on HIV Pathogenesis, Treatment and Prevention, 22-25 July 2007, Sydney

HIV viraemia may explain increased risk of cardiovascular disease, death and other serious events in patients interrupting treatment in the SMART trial: new study to randomise patients with CD4 counts >500 to start immediate treatment or defer to <350 cells/mm3

CD4 increases in immunological non-responders despite suppressive therapy following switch to nuke-sparing regimen of ATZ/SQV/r

Darunavir/r shows superiority over lopinavir/r at 48 weeks in TITAN trial

Maraviroc fails to show non-inferiority to efavirenz in treatment-naive patients: 48 week results

Importance of using maraviroc in combination with other active drugs in treatment-experienced patients

Week 48 raltegravir results in treatment-naive phase II dose-finding study

DUET studies clarify antiviral efficacy of etravirine and cross-resistance profile to other NNRTIs

Boosting atazanavir in treatment-naive patients, and impact on lipids after switching from lopinavir/r

Saquinavir/r vs lopinavir/r in treatment-naive patients

Fosamprenavir/r vs atazanvir/r in treatment-naive patients

Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young infants; interim results from the CHER study

Very low transmission rates among breastfeeding women receiving ART

Post navigation